A bioprinted breast cancer model using bioinks of decellularized breast tissue for studying cancer stemness, invasion, and drug efficacy.
Blanco-Fernandez B., Bagci G., Perez-Amodio S., Rey-Vinolas S., Ximenes-Carballo C., Gato-Diaz U.
Laboratory Study, published in Acta Biomater (2025) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Laboratory Study
- Journal
- Acta Biomater (2025)
- Country
- England
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 40721188
- DOI
- 10.1016/j.actbio.2025.07.054
Abstract (original English)
Breast cancer 3D in vitro systems that replicate key tumor characteristics could assist drug discovery by providing more clinically translational models. Breast tumors are formed by hierarchically organized cancer and stromal cells and the extracellular matrix, all of which contribute to the disease progression and treatment response. 3D-bioprinting has enabled the creation of anatomically relevant constructs that better recapitulate the tumor architecture. The extracellular matrix's role in the tumor outcome has motivated the development of biomimetic bioinks. Among them, bioinks based on decellularized mammary glands can mimic many native biological cues. This work aims to develop a bioprinted 3D in vitro model of breast cancer using a biomimetic bioink based on decellularized mammary glands, and to investigate the effect of this bioink on the malignancy and drug resistance of breast cancer cells. The biomimetic bioink supported cell stemness, invasion, and an immunosuppressive environment but did not promote drug resistance. We also tested the effect of supplementing the bioink with collagen I, which is highly expressed in breast cancer, on breast cancer cells. We observed a higher expression of malignancy markers (COL1A1) and invasion markers (CDH2, MMP2). Next, we bioprinted a cancer model using human adipose mesenchymal stem cells and breast cancer cells to replicate tumo
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.